Zelira Therapeutics (AU:ZLD) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Zelira Therapeutics reported a net cash inflow of $586,000 for the quarter ending September 2024, driven primarily by $2,098,000 in proceeds from borrowings. However, the company faced significant cash outflows from operating activities amounting to $1,555,000, indicating a challenging financial quarter despite the influx from financing activities.
For further insights into AU:ZLD stock, check out TipRanks’ Stock Analysis page.